Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation.
Lung Cancer(2018)
摘要
•Avitinib is a novel third-generation EGFR TKI.•Avitinib is well tolerated and efficacious in T790M-positive patients.•The penetrability of avitinib to the BBB is weak.•Avitinib could control of asymptomatic brain metastases to a certain extent.
更多查看译文
关键词
Third generation EGFR TKI,T790M mutation,Penetration rate,Cerebrospinal fluid,Brain metastases
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络